重症肌无力治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球重症肌无力治疗市场价值为 18 亿美元，预计到 2034 年将以 7.6% 的复合年增长率成长，达到 38 亿美元。这一稳定的成长轨迹反映了全球对重症肌无力的认识不断提高，重症肌无力是一种以骨骼肌无力为特征的自身免疫性神经肌肉疾病。随着已开发地区和新兴地区的诊断能力不断提高，疾病的早期发现变得越来越频繁。这导致对及时有效的治疗干预的需求激增。老年人口的不断增长是导致病例数量上升的关键因素，由于老年人的免疫系统自然衰退，他们更容易患上自体免疫疾病。

此外，患者对非侵入性药物治疗而非手术治疗的偏好也推动了对创新疗法的需求不断增长。医疗支出的增加、优惠的报销政策以及政府对罕见疾病管理的支持进一步推动了重症肌无力治疗市场的扩张。随着製药公司加强对研发的投资，将先进的治疗方案推向市场，竞争格局也正在转变。药品製造商优先考虑标靶治疗，以改善生活品质并减少副作用，而生物技术公司和医疗机构之间的合作则支持更快的创新。这些因素共同表明，市场将在患者需求和技术进步的推动下实现长期可持续增长。

市场按治疗类型细分，包括药物治疗、疗法和手术。其中，药品部门预计将推动最大份额的收入成长，预计复合年增长率为 7.7%，市场价值预计到 2034 年将达到 29 亿美元。全球重症肌无力病例的激增增加了对可靠药物治疗的需求，包括单株抗体和免疫抑制剂。同时，静脉注射免疫球蛋白 (IVIG) 和血浆置换等疗法因其在治疗中度至重度症状方面的临床效果而越来越受欢迎。

根据分销管道，市场分为医院药房、零售药房和电子商务平台。医院药局占了相当大的份额，2024 年的收入将达到 10 亿美元。这种增长主要是由于人们对需要医疗监督和专门管理的生物疗法的偏好日益增加。此外，先进生物治疗的保险覆盖范围也支持基于医院的分销模式。

2024 年美国重症肌无力治疗市值为 7.333 亿美元。美国 FDA 的监管支持（包括快速审批和孤儿药指定）正在鼓励新疗法的推出。在领先製药公司的支持下，美国医疗保健生态系统在推动创新和改善患者治疗效果方面继续发挥关键作用。

该行业的主要参与者包括强生、辉瑞、Alexion Pharmaceuticals、安进、艾伯维、安斯泰来製药、梯瓦製药工业、罗氏製药、三菱田边製药公司、UCB 製药、基立福、葛兰素史克、诺华、赛诺菲和博士伦製药公司。这些公司正在积极扩大其治疗管道，重点关注单株抗体、免疫抑制剂和策略合作伙伴关係，以推进研发并简化全球患者的市场准入。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 重症肌无力盛行率上升
    • 生物疗法的进展
    • 老年人口不断增加
    • 有利的监管批准和研究资金
  • 产业陷阱与挑战
    • 治疗费用高昂
    • 认识不足和误诊
• 成长潜力分析
• 监管格局
• 技术格局
• 管道分析
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按治疗类型，2021 - 2034 年

• 主要趋势
• 药物
  • 胆碱酯酶抑制剂
  • 皮质类固醇
  • 免疫抑制剂
  • 单株抗体
• 治疗
  • 静脉注射免疫球蛋白（IVIG）
  • 血浆置换
• 手术

第六章：市场估计与预测：依疾病类型，2021 - 2034 年

• 主要趋势
• 眼部重症肌无力
• 全身性重症肌无力

第七章：市场估计与预测：按配销通路，2021 - 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 电子商务

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• AbbVie
• Alexion Pharmaceuticals
• Amgen
• Argenx
• Astellas Pharma
• Bausch Health Companies
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Grifols
• Mitsubishi Tanabe Pharma Corporation
• Novartis
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries
• UCB Pharma

The Global Myasthenia Gravis Treatment Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 7.6% to reach USD 3.8 billion by 2034. This steady growth trajectory reflects a rising global awareness of myasthenia gravis, an autoimmune neuromuscular disorder marked by weakness in the skeletal muscles. As diagnostic capabilities continue to improve across developed and emerging regions, early-stage identification of the disease is becoming more frequent. This is prompting a surge in the demand for timely and effective treatment interventions. The growing elderly population, who are more prone to autoimmune diseases due to a naturally declining immune system, is playing a key role in driving case numbers upward.

Additionally, evolving patient preferences for non-invasive, pharmaceutical-based treatments over surgical options are contributing to the rising demand for innovative therapies. Increased healthcare expenditure, favorable reimbursement policies, and government support for rare disease management are further fueling the expansion of the myasthenia gravis treatment market. The competitive landscape is also witnessing a shift as pharmaceutical companies invest more aggressively in research and development to bring advanced treatment options to market. Drug manufacturers are prioritizing targeted therapies to improve quality of life and reduce side effects, while collaborations between biotech firms and medical institutions are supporting faster innovation. These elements collectively point to a market that is poised for long-term, sustainable growth driven by both patient needs and technological progress.

The market is segmented by treatment types, including medication, therapy, and surgery. Among these, the medication segment is expected to drive the largest portion of revenue growth, with a projected CAGR of 7.7% and a market value forecast to reach USD 2.9 billion by 2034. The surge in global cases of myasthenia gravis is increasing the demand for reliable pharmaceutical treatments, including monoclonal antibodies and immunosuppressants. In parallel, therapies such as intravenous immunoglobulin (IVIG) and plasmapheresis are gaining popularity due to their clinical effectiveness in managing moderate to severe symptoms.

Based on distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and e-commerce platforms. Hospital pharmacies accounted for a significant share, with revenues reaching USD 1 billion in 2024. This growth is largely due to the rising preference for biologic therapies that require medical supervision and specialized administration. Additionally, insurance coverage for advanced biological treatments is supporting hospital-based distribution models.

The U.S. Myasthenia Gravis Treatment Market was valued at USD 733.3 million in 2024. Regulatory support from the U.S. FDA, including fast-track approvals and orphan drug designations, is encouraging the launch of new therapies. The U.S. healthcare ecosystem, backed by leading pharmaceutical firms, continues to play a crucial role in pushing forward innovation and improving patient outcomes.

Key players in the industry include Johnson & Johnson, Pfizer, Alexion Pharmaceuticals, Amgen, AbbVie, Astellas Pharma, Teva Pharmaceutical Industries, F. Hoffmann-La Roche, Mitsubishi Tanabe Pharma Corporation, UCB Pharma, Grifols, GlaxoSmithKline, Novartis, Sanofi, and Bausch Health Companies. These companies are actively expanding their treatment pipelines with a focus on monoclonal antibodies, immunosuppressants, and strategic partnerships to advance R&D and streamline market access for patients worldwide.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of myasthenia gravis
    • 3.2.1.2 Advancements in biologic therapies
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Favorable regulatory approvals and research funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Limited awareness and misdiagnosis
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Cholinesterase inhibitors
  • 5.2.2 Corticosteroids
  • 5.2.3 Immunosuppressants
  • 5.2.4 Monoclonal antibodies
• 5.3 Therapy
  • 5.3.1 Intravenous immunoglobulin (IVIG)
  • 5.3.2 Plasmapheresis
• 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Ocular myasthenia gravis
• 6.3 Generalized myasthenia gravis

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Alexion Pharmaceuticals
• 9.3 Amgen
• 9.4 Argenx
• 9.5 Astellas Pharma
• 9.6 Bausch Health Companies
• 9.7 F. Hoffmann-La Roche
• 9.8 GlaxoSmithKline
• 9.9 Grifols
• 9.10 Mitsubishi Tanabe Pharma Corporation
• 9.11 Novartis
• 9.12 Pfizer
• 9.13 Sanofi
• 9.14 Teva Pharmaceutical Industries
• 9.15 UCB Pharma